No Data
No Data
Express News | SpringWorks Therapeutics Inc : Wedbush Cuts to Neutral From Outperform; Cuts Target Price to $47 From $81
Express News | Merck KGaA CEO Says This Is a Firm and Final Offer That Has Been Accepted, When Asked About the Potential of Any Rival Bids for SpringWorks
Express News | Merck KGaA CEO: US Medicines Market Is Highly Attractive, Enhancing Our Scale in US Is a Key Part of Logic Behind SpringWorks Deal
Express News | Merck KGaA CEO Says Our M&a Strategy Will Remain Very Disciplined, Life Science Unit to Remain a Focus
Express News | SpringWorks Therapeutics: Co to Pay Merck KGaA $145.6 Mln Termination Fee if Deal Is Terminated Under Some Circumstances
Germany's Merck's Deal to Acquire SpringWorks Makes Strategic Sense, but Price in Focus -- Market Talk